Blocking Characteristics of hERG, hNav1.5, and hKvLQT1/hminK after Administration of the Novel Anti‐Arrhythmic Compound AZD7009

Introduction: AZD7009 is a novel anti‐arrhythmic compound under development for short‐ and long‐term management of atrial fibrillation and flutter. Electrophysiological studies in animals have shown high anti‐arrhythmic efficacy, predominant action on atrial electrophysiology, and low proarrhythmic activity. The main aim of this study was to characterize the blocking effects of AZD7009 on the human ether‐a‐go‐go‐related gene (hERG), the hNav1.5, and the hKvLQT1/hminK currents.

[1]  A. Waldo,et al.  Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. , 2004, Journal of cardiovascular electrophysiology.

[2]  J. Aronson,et al.  An improved model for the binding of lidocaine and structurally related local anaesthetics to fast‐inactivated voltage‐operated sodium channels, showing evidence of cooperativity , 2004, British journal of pharmacology.

[3]  B. Sakmann,et al.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.

[4]  Marc A. Vos,et al.  Probing the Contribution of IKs to Canine Ventricular Repolarization: Key Role for &bgr;-Adrenergic Receptor Stimulation , 2003, Circulation.

[5]  L. Carlsson,et al.  Block of HERG‐Carried K+ Currents by the New Repolarization Delaying Agent H 345/52 , 2003, Journal of cardiovascular electrophysiology.

[6]  R. Kass,et al.  Common Molecular Determinants of Flecainide and Lidocaine Block of Heart Na+ Channels , 2003, The Journal of general physiology.

[7]  Owe Orwar,et al.  A cell-based bar code reader for high-throughput screening of ion channel-ligand interactions. , 2002, Analytical chemistry.

[8]  Colleen E. Clancy,et al.  Channel Openings Are Necessary but not Sufficient for Use-dependent Block of Cardiac Na+ Channels by Flecainide , 2002, The Journal of general physiology.

[9]  Jiesheng Kang,et al.  Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. , 2001, The Journal of pharmacology and experimental therapeutics.

[10]  C Antzelevitch,et al.  Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. , 2001, American journal of physiology. Heart and circulatory physiology.

[11]  Gea-Ny Tseng,et al.  IKr: The hERG Channel , 2001 .

[12]  L. Isom.  Sodium Channel β Subunits: Anything but Auxiliary , 2001 .

[13]  J. Hancox,et al.  Familial And Acquired Long QT Syndrome And The Cardiac Rapid Delayed Rectifier Potassium Current , 2000, Clinical and experimental pharmacology & physiology.

[14]  T J Campbell,et al.  Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel. , 2000, Cardiovascular research.

[15]  H. Wellens,et al.  Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. , 2000, Cardiovascular research.

[16]  John S. Mitcheson,et al.  Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.

[17]  M. Jiang,et al.  Use-dependent 'agonist' effect of azimilide on the HERG channel. , 1999, The Journal of pharmacology and experimental therapeutics.

[18]  S. Nattel,et al.  Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. , 1999, The American journal of cardiology.

[19]  CharlesAntzelevitch,et al.  Sodium Channel Block With Mexiletine Is Effective in Reducing Dispersion of Repolarization and Preventing Torsade de Pointes in LQT2 and LQT3 Models of the Long-QT Syndrome , 1997 .

[20]  M. Sanguinetti,et al.  Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel , 1996, Nature.

[21]  Jacques Barhanin,et al.  KvLQT1 and IsK (minK) proteins associate to form the IKS cardiac potassium current , 1996, Nature.

[22]  D. Snyders,et al.  High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.

[23]  Gary Yellen,et al.  The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.

[24]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[25]  J. Maylie,et al.  The novel class III antiarrhythmics NE-10064 and NE-10133 inhibit IsK channels expressed in Xenopus oocytes and IKs in guinea pig cardiac myocytes. , 1994, Biochemical and biophysical research communications.

[26]  J. Warmke,et al.  A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Carlsson,et al.  Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. , 1993, The Journal of pharmacology and experimental therapeutics.

[28]  E. Carmeliet.  Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. , 1993, Circulation research.

[29]  W. Lindner,et al.  Stereoselective Interactions of (R)-and (S)-Propafenone with the Cardiac Sodium Channel , 1992, Journal of cardiovascular pharmacology.

[30]  S. Roberds,et al.  Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. , 1992, Molecular pharmacology.

[31]  R Horn,et al.  Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. Strichartz,et al.  Fundamental Properties of Local Anesthetics. II. Measured Octanol: Buffer Partition Coefficients and pKa Values of Clinically Used Drugs , 1990, Anesthesia and analgesia.

[33]  C F Starmer,et al.  Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics. , 1984, Biophysical journal.

[34]  R. Tsien,et al.  Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status , 2018, Journal of clinical medicine research.

[35]  B. Katzung,et al.  Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. , 1977, Biochimica et biophysica acta.

[36]  B. Hille,et al.  Local anesthetics: hydrophilic and hydrophobic pathways for the drug- receptor reaction , 1977, The Journal of general physiology.